Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 54.6% from a year ago
Cash & equivalents stood at $28.37M at the end of Q1 FY2026, up 54.6% from a year earlier and down 18.2% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Cash & equivalents amounted to 28.2% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +54.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 34.69M USD
- Year-over-year change
- +55.8%
- 4-year CAGR
- +36.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.69M | +55.8% |
| FY2024 | 2024-12-31 | 22.26M | -27.2% |
| FY2023 | 2023-12-31 | 30.56M | +54.5% |
| FY2022 | 2022-12-31 | 19.78M | +99.1% |
| FY2021 | 2021-12-31 | 9.94M | — |
Cash & Equivalents vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +54.6% is the 3rd highest of 11, against a peer median of -42.6%.
- Cash & equivalents amounts to 28.2% of total assets for OBIO, versus a peer median of 21.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $184.15M USD | +283.0% | +35.0% | 76.2% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $80.89M USD | +50.4% | +1.8% | 59.9% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M USD | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $21.76M USD | -46.0% | +4.8% | 18.2% | |
| Mar 2026 | $14.74M USD | -83.9% | +27.2% | 7.7% | |
| Mar 2026 | $12.06M USD | -59.0% | -40.4% | 8.1% | |
| Mar 2026 | $7.24M USD | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding OBIO) | — | -42.6% | +4.7% | 21.6% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.94M | 19.78M | 30.56M | 22.26M | 34.69M |
| Short-term Investments | 958K | 64M | 57.04M | 44.55M | 71.82M |
| Net Receivables | 121K | 96K | 99K | 92K | 95K |
| Inventory | 68K | 276K | 146K | 173K | 310K |
| Other Current Assets | 0 | 533K | 1.27M | 2.09M | 994K |
| Total Current Assets | 11.32M | 84.69M | 89.11M | 69.17M | 107.91M |
| Property, Plant & Equipment (Net) | 1.12M | 3.68M | 2.83M | 3.49M | 3.21M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 398K | 2.5M | 2.5M | 2.5M | 2.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 690K | 4.71M | 769K | 1.02M | 1.24M |
| Total Non-current Assets | 2.21M | 10.88M | 6.1M | 7M | 6.95M |
| Total Assets | 13.53M | 95.57M | 95.21M | 76.17M | 114.86M |
| Account Payables | 2.03M | 3.97M | 2.9M | 5.13M | 6.1M |
| Short-term Debt | 2M | 0 | 0 | 0 | 751K |
| Tax Payables | 1K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.54M | 6.44M | 2.51M | 4.44M | 0 |
| Other Current Liabilities | 2M | 4.57M | 2.66M | 2.61M | 9.89M |
| Total Current Liabilities | 12.24M | 18.57M | 11.21M | 16.21M | 16.74M |
| Long-term Debt | 3.67M | 9.49M | 0 | 14.29M | 936K |
| Deferred Tax Liabilities | 0 | 0 | (14.92M) | 0 | 0 |
| Deferred Revenue (Non-current) | 16.86M | 13.1M | 14.92M | 10.99M | 0 |
| Other Non-current Liabilities | 51.99M | 196K | 14.92M | 40K | 33.81M |
| Total Non-current Liabilities | 72.52M | 24.47M | 15.96M | 27.01M | 34.74M |
| Total Liabilities | 84.76M | 43.04M | 27.17M | 43.22M | 51.48M |
| Common Stock | 160M | 2K | 4K | 4K | 6K |
| Retained Earnings | (166.13M) | (199.73M) | (248.85M) | (309.88M) | (362.58M) |
| Accumulated OCI | (211.45M) | (8K) | (10K) | 52K | 60K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (71.23M) | 52.53M | 68.04M | 32.96M | 63.38M |
| Total Debt | 5.67M | 11.87M | 1.69M | 16.53M | 1.69M |
| Net Debt | (4.27M) | (7.91M) | (28.87M) | (5.73M) | (33M) |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.